• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Prenatal and New-born Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Product Image

Prenatal and New-born Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • ID: 2776215
  • March 2014
  • Region: Global
  • 87 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • Ariosa Diagnostics, Inc.
  • Illumina, Inc.
  • Natera, Inc.
  • PerkinElmer, Inc.
  • Sequenom, Inc.
  • MORE

'Prenatal and New-Born Genetic Testing Market (PCR, FISH, aCGH, NIPT and MSS): Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019'

Prenatal testing and diagnosis have enabled the detection of certain genetic abnormalities in as early as 8 to 10 weeks of gestation and also helps to determine the sex of the fetus. Prenatal and newborn genetic testing is referred to as the utilization of screening/diagnostic procedures for a fetus or a new born baby to detect chromosomal abnormalities such as Down syndrome, Patau syndrome and Edward syndrome.

This report studies the global prenatal and newborn genetic testing market from two perspectives namely, types of technologies and the major geographic markets. The global prenatal and newborn genetic testing market by technology has been segmented as diagnostic technique and screening methods. Diagnostic technique is further classified as polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) and array-comparative genomic hybridization (aCGH). Similarly, screening methods are further categorized as non-invasive prenatal tests and maternal serum screening.

Geographically, the report READ MORE >

FEATURED COMPANIES

  • Ariosa Diagnostics, Inc.
  • Illumina, Inc.
  • Natera, Inc.
  • PerkinElmer, Inc.
  • Sequenom, Inc.
  • MORE

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.4 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Prenatal and Newborn Genetic Testing Market (2012 & 2019)
2.2 Global Prenatal and Newborn Genetic Testing Market, by Segments, 2012 (USD Million)

Chapter 3 Prenatal and Newborn Genetic Testing Market Overview
3.1 Introduction and Market Definition
3.2 Future Market Outlook
3.3 Regulatory and Reimbursement Scenario for Prenatal and Newborn Screening
3.4 Market Dynamics
3.4.1 Drivers
3.4.2 Restraints
3.4.3 Market Opportunities
3.5 Porter’s Five Forces Analysis: Global Prenatal and Newborn Genetic Testing Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis

Chapter 4 Prenatal and Newborn Genetic Testing Market, by Technology
4.1 Overview
4.1.1 Global Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 – 2019 (USD Million)
4.2 Diagnostic Techniques
4.2.1 Global Diagnostic Techniques Market Revenue, by Types, 2012 – 2019 (USD Million)
4.2.2 Polymerase Chain Reaction (PCR)
4.2.3 Fluorescence In-Situ Hybridization (FISH)
4.2.4 Array-Comparative Genomic Hybridization (aCGH)
4.3 Screening Methods
4.3.1 Global Screening Methods Market Revenue, by Types, 2012 – 2019 (USD Million)
4.3.2 Non-invasive Prenatal Tests (MaterniT21 PLUS, Verifi, Harmony, Panorama, NIFTY, PrenaTest and Bambni Test)
4.3.3 Maternal Serum Screening (MSS)

Chapter 5 Prenatal and Newborn Genetic Testing Market, by Geography
5.1 Overview
5.1.1 Global Prenatal and Newborn Genetic Testing Market Revenue, by Geography2012 – 2019 (USD Million)
5.2 North America
5.2.1 North America Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
5.2.2 North America Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
5.2.3 North America Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
5.3 Europe
5.3.1 Europe Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
5.3.2 Europe Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
5.3.3 Europe Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
5.4 Asia - Pacific
5.4.1 Asia-Pacific Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
5.4.2 Asia-Pacific Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
5.4.3 Asia-Pacific Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
5.5 Rest of the World (RoW)
5.5.1 RoW Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
5.5.2 RoW Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
5.5.3 RoW Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)

Chapter 6 Competitive Landscape
6.1 Market Share Analysis, by Key Players, 2012 (%)

Chapter 7 Recommendations
7.1 Market Strategy for Success
7.1.1 Focus on forming alliances with diagnostic service providers in Asia-Pacific countries
7.1.2 Emphasis on improving technology in order to increase accuracy, reduce the duration of result generation and price
7.2 Barriers and Future Assumptions
7.2.1 Lack of awareness about prenatal and newborn genetic testing in some Asian countries
7.2.2 Regulatory compliance and ethical issues

Chapter 8 Company Profiles
8.1 Agilent Technologies, Inc.
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.5 Recent Developments
8.2 Ariosa Diagnostics, Inc.
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategies
8.2.5 Recent Developments
8.3 Bio-Rad Laboratories, Inc.
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.5 Recent Developments
8.4 Illumina, Inc.
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.4.5 Recent Developments
8.5 Laboratory Corporation of America Holdings (LabCorp)
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.5.5 Recent Developments
8.6 Natera, Inc.
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Developments
8.7 PerkinElmer, Inc.
8.7.1 Company Overview
8.7.2 Financial Overview
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.7.5 Recent Developments
8.8 Sequenom, Inc.
8.8.1 Company Overview
8.8.2 Financial Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.8.5 Recent Developments

List of Figures

FIG. 1 Prenatal and Newborn Genetic Testing: Market Segmentation
FIG. 2 Global Prenatal and Newborn Genetic Testing Market, by Segments, 2012 (USD Million)
FIG. 3 Adoption Curve Analysis for Genetic Testing Market
FIG. 4 Porter’s Five Forces Analysis: Global Prenatal and Newborn Genetic Testing Market
FIG. 5 Market Attractiveness Analysis: Global Prenatal and Newborn Genetic Testing Market, 2012
FIG. 6 Global PCR Market Revenue, 2012 – 2019 (USD Million)
FIG. 7 FISH Procedural Steps
FIG. 8 Global FISH Market Revenue, 2012 – 2019 (USD Million)
FIG. 9 Global aCGH Market Revenue, 2012 – 2019 (USD Million)
FIG. 10 Global NIPT Market Revenue, 2012 – 2019 (USD Million)
FIG. 11 Global MSS Market Revenue, 2012 – 2019 (USD Million)
FIG. 12 Global Prenatal and Newborn Genetic Testing: Market Share, by Key Players, 2012 (%)
FIG. 13 Annual Sales: Agilent Technologies, Inc., 2010 – 2012 (USD Million)
FIG. 14 Annual Sales: Bio-Rad Laboratories, Inc., Clinical Diagnostics Segment, 2010 – 2012 (USD Million)
FIG. 15 Annual Sales: Illumina, Inc., 2010 – 2012 (USD million)
FIG. 16 Annual Sales: LabCorp, 2010– 2012 (USD Million)
FIG. 17 Annual Sales: PerkinElmer, Inc. (Human Health Segment), 2010 – 2012 (USD Million)
FIG. 18 Annual Sales: Sequenom Inc., 2010–2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Prenatal and Newborn Genetic Testing Market (2012 & 2019)
TABLE 2 Technological Approach for Non-Invasive Prenatal Screening Tests
TABLE 3 Global Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 – 2019 (USD Million)
TABLE 4 Global Diagnostic Techniques Market Revenue, by Types, 2012 – 2019 (USD Million)
TABLE 5 Global Screening Methods Market Revenue, by Types, 2012 – 2019 (USD Million)
TABLE 6 Global Prenatal and Newborn Genetic Testing Market Revenue, by Geography, 2012 – 2019 (USD Million)
TABLE 7 North America Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 8 North America Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 9 North America Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 10 Europe Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 11 Europe Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 12 Europe Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 13 Asia-Pacific Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 14 Asia-Pacific Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 15 Asia-Pacific Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 16 RoW Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
TABLE 17 RoW Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
TABLE 18 RoW Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)

FEATURED COMPANIES

  • Ariosa Diagnostics, Inc.
  • Illumina, Inc.
  • Natera, Inc.
  • PerkinElmer, Inc.
  • Sequenom, Inc.
  • MORE

Genetic testing is a systematic diagnostic and screening technique usually applied to detect risk of genetic disorders in unicellular and multicellular organisms. This technique in a broader sense includes biochemical tests for the detection of possible presence of genetic diseases or mutant forms of genes associated with increased risk of developing genetic disorders. Genetic testing is broadly segmented as newborn screening, diagnostic testing, carrier testing, prenatal testing, pre-implantation testing, predictive and forensic testing. Prenatal and newborn genetic testing market is segmented on the basis of technology and geography. Prenatal and newborn genetic testing refers to the utilization of screening/diagnostic procedures of a fetus or a new born baby to detect chromosomal abnormalities such as Down syndrome, Patau syndrome and Edward syndrome.

The prenatal and newborn genetic testing market by technology is further segmented as diagnostic tests and screening tests. The diagnostic tests segment covers the global market for techniques such as polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH) and array comparative genomic hybridization (aCGH), while screening tests include non-invasive prenatal testing (NIPT) and maternal serum screening (MSS). The prenatal and newborn genetic testing market is driven by increasing maternal age and late pregnancies, technological advancements and growing awareness about genetic disorders in the fetus.

Diagnostic tests are more effective, accurate and preferred option for detection of chromosome abnormalities compared to the screening methods. PCR technique accounted for the largest share among diagnostic tests category due to its varied applications and high efficiency. On the other hand, aCGH and FISH are most growing and developing diagnostic techniques owing to their high efficiency. While NIPT market (screening methods) is growing at a highest CAGR from 2013 to 2019.

North America is the largest market for prenatal and newborn genetic testing owing to the non-invasive nature of NIPT tests that completely eliminates the risk of miscarriage associated with invasive tests such as amniocentesis and CVS (Chorionic Villus Sampling). While Asia-Pacific market has a highest CAGR after North America as this market is driven by factors such as developing awareness about genetic testing, high prevalence of genetic diseases, increasing population and economic development. Rest of the World (RoW) is the untapped market due to lack of awareness, cultural barriers in the Gulf and African countries, and weak economic conditions in some African countries.

The diagnostic testing techniques market consists of key players such as Bio-Rad Laboratories, Agilent Technologies, Perkin Elmer and Ariosa Diagnostics. Major players of the screening methods market are Sequenom, Inc., Illumina, Inc. and Natera, Inc. Overall Sequenom, Inc. and Verinata Health are the major market players of global prenatal and newborn genetic testing market because of their initial product launch in this market.

- Agilent Technologies, Inc.
- Ariosa Diagnostics, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Laboratory Corporation of America Holdings (LabCorp)
- Natera, Inc.
- PerkinElmer, Inc.
- Sequenom, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos